LifeArc portfolio company RQ Bio’s antibody enters clinical trials
LifeArc Ventures’ portfolio company RQ Biotechnology has announced that the first of its discovered monoclonal antibodies to…
LifeArc Ventures’ portfolio company RQ Biotechnology has announced that the first of its discovered monoclonal antibodies to…
Dave Powell on why LifeArc is evolving the way we do our science – and the difference we hope it will make to people’s lives.
Three-year partnership to improve healthcare for thousands of people across Europe living with bronchiectasis.
First major funding call announced as part of our £100m Chronic Respiratory Infection Translational Challenge
More than 300,000 people in the UK are living with bronchiectasis and more than 10,000 have been diagnosed with cystic fibrosis.
LifeArc CEO Dr Melanie Lee welcomes the Government’s restatement of its commitment to increase R&D funding in today’s Autumn statement: “Today the Chancellor made it clear that UK life science is a key driver of growth. “I am delighted that promises to raise the research and development (R&D) budget have been protected. It is the […]
Trials will examine the impact of home monitoring and machine learning decision support algorithms for people with CF and bronchiectasis.
Seed funding will be used to scale the solution through the application of machine learning
Ahead of the Autumn Statement, LifeArc and other leading life science organisations have written to the Chancellor…